Claims on tissue plasminogen activator
β Scribed by Crespi, R. Stephen
- Book ID
- 109757729
- Publisher
- Nature Publishing Group
- Year
- 1989
- Tongue
- English
- Weight
- 258 KB
- Volume
- 337
- Category
- Article
- ISSN
- 0028-0836
- DOI
- 10.1038/337317a0
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Defibrotide, a polydeoxyribonucleotide of mammalian origin, has been shown to reduce the blood level of the plasminogen activator inhibitor, and so to increase the activity of tissue plasminogen activator without any adverse effect. A randomized, double-blind, placebo-controlled study has been done
## Abstract Tissue plasminogen activator (tPA) is the only FDAβapproved treatment of thrombotic stroke and is a major parenchymal serine protease in the brain. However, it has been implicated in a plethora of brain pathologies, raising concern about its use as a safe therapeutic. tPA is thought to